Help

Data Analysis for Promonitor® Kits

Use the free online MyAssays service to transform your Promonitor® measurement data to meaningful results in record time.

There is no complicated software to install, learn or configure. Simply provide your raw data and parameters into the kit page and your results are calculated automatically. Your tailored report is available immediately through your web browser. Optional Premium tools are available to work within Microsoft Excel using the MyAssays Add-In, or with MyAssays Desktop to work privately on your own system keeping all of your data in-house..

Register now to process measurement data for these kits:

Promonitor® Kits

Kit

Product Ref.

Assays Available

Promonitor®-IFX

5060230000

Quantitative measure of infliximab levels

Promonitor®-Anti-IFX

5070230000

Quantitative measure of anti-infliximab antibodies

Promonitor®-ADL

5080230000

Quantitative measure of adalimumab levels

Promonitor®-Anti-ADL

5090230000

Quantitative measure of anti-adalimumab antibodies

Promonitor®-ETN

5110230000

Quantitative measure of etanercept levels

Promonitor®-Anti-ETN

5120230000

Quantitative measure of anti-etanercept antibodies

Promonitor®-RTX

5130230000

Quantitative measure of rituximab levels

Promonitor®-Anti-RTX

5140230000

Quantitative measure of anti-rituximab antibodies

Promonitor®-GLM

5200230000

Quantitative measure of golimumab levels

Promonitor®-Anti-GLM

5210230000

Quantitative measure of anti-golimumab antibodies

Promonitor®-VDZ

539xx30000

Quantitative measure of vedolizumab antibodies

Promonitor®-ANTI-VDZ

54015xx30000

Quantitative measure of ANTI-vedolizumab antibodies

Promonitor®-UTK

5371530000

Quantitative measure of ustekinumab levels

Promonitor®-ANTI-UTK

5381530000

Quantitative measure of anti-ustekinumab antibodies

Promonitor®-TCZ

In development

Quantitative measure of tocilizumab levels

Promonitor®-Anti-TCZ

In development

Quantitative measure of anti-tocilizumab antibodies

Promonitor®-CTZ

In development

Quantitative measure of certolizumab levels

Promonitor®-Anti-CTZ

In development

Quantitative measure of anti-certolizumab antibodies

Promonitor®-UTK

In development

Quantitative measure of ustekinumab levels

Promonitor®-Anti-UTK

In development

Quantitative measure of anti-ustekinumab antibodies

Monitoring Biological Drugs

Chronic inflammatory diseases are highly heterogeneous conditions characterized by over production of cytokines, essential components in a body's immune response, that when disregulated play a critical role in the pathogenesis of these diseases. Among the cytokines tumor necrosis factor alpha (TNFα) is a key trigger in the induction of the inflammatory cascade and therefore of disease symptoms.

The new generations of biological anti-TNFα drugs are recombinant antibody molecules that target TNFα thereby limiting the extent to which the inflammatory cascade is triggered.

Therapies based on this novel class of biological drugs have provided a much-needed alternative to clinicians for the treatment of chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease (Crohn's disease and ulcerative colitis). Despite the widespread success of these drugs however some patients do not respond satisfactorily or show a diminished response after prolonged drug treatment. The failure to respond to these treatments is primarily due to the immunogenicity of the drugs themselves, that is, the patient creates antibodies that target the drug itself thus neutralizing the beneficial effect of treatment and potentially even triggering an adverse drug response.

Objective Selection of Therapy and Dosage

Administration of biologic drugs should always be performed in parallel with the close monitoring of the patient response to the drug in order to evaluate the efficacy of treatment and if necessary to adjust dosage or switch therapy.

Currently the assessment of patient response to the treatment of autoimmune and inflammatory diseases is based on patient reporting of symptom severity. While such measures are useful in assessing the impact of treatment on a patient’s quality of life this approach fails to provide an objective biological insight into the efficacy of treatment. The use of PROMONITOR® allows individualized optimization of treatment regimes, thereby increasing the clinical benefit to patients and avoiding the waste of time, money and opportunity spent on ineffective treatments. The goal of objectively measuring drug response is achieved by PROMONITOR® through the measurement of both drug bioavailability and immunogenicity.

Promonitor® is a product developed by Proteomika and distributed worldwide. Please contact your local distributor to place an order.


Send Message to MyAssays...